Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans

被引:0
|
作者
A Gaedigk
A Bhathena
L Ndjountché
R E Pearce
S M Abdel-Rahman
S W Alander
L DiAnne Bradford
J Steven Leeder
机构
[1] Children's Mercy Hospital & Clinics,Division of Clinical Pharmacology and Experimental Therapeutics
[2] Morehouse School of Medicine,undefined
来源
The Pharmacogenomics Journal | 2005年 / 5卷
关键词
SNPs; haplotype; dextromethorphan; African American;
D O I
暂无
中图分类号
学科分类号
摘要
Cytochrome P4502D6 (CYP2D6) genotyping reliably predicts poor metabolizer phenotype in Caucasians, but is less accurate in African Americans. To evaluate discordance we have observed in phenotype to genotype correlation studies, select African American subjects were chosen for complete resequencing of the CYP2D6 gene including 4.2 kb of the CYP2D7-2D6 intergenic region. Comparisons were made to a CYP2D6*1 reference sequence revealing novel SNPs in the upstream, coding and intervening sequences. These sequence variations, defining four functional alleles (CYP2D6*41B, *45A and B and *46), were characterized for their ability to influence splice site strength, transcription level or catalytic protein activity. Furthermore, their frequency was determined in a population of 251 African Americans. A −692TGTG deletion (CYP2D6*45B) did not significantly decrease gene expression, nor could any other upstream SNP explain a genotype-discordant case. CYP2D6*45 and *46 have a combined frequency of 4% and can be identified by a common SNP. Carriers are predicted to exhibit an extensive or intermediate CYP2D6 phenotype.
引用
收藏
页码:173 / 182
页数:9
相关论文
共 50 条
  • [1] Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans
    Gaedigk, A
    Bhathena, A
    Ndjountché, L
    Pearce, RE
    Abdel-Rahman, SM
    Alander, SW
    Bradford, LD
    Leeder, JS
    PHARMACOGENOMICS JOURNAL, 2005, 5 (03): : 173 - 182
  • [2] Erratum: Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans
    A Gaedigk
    A Bhathena
    L Ndjountché
    R E Pearce
    S M Abdel-Rahman
    S W Alander
    L DiAnne Bradford
    J Steven Leeder
    The Pharmacogenomics Journal, 2005, 5 : 276 - 276
  • [3] Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans (vol 5, pg 173, 2005)
    Gaedigk, A
    Bhathena, A
    Ndjountché, L
    Pearce, RE
    Abdel-Rahman, SM
    Alander, SW
    Bradford, LD
    Leeder, JS
    PHARMACOGENOMICS JOURNAL, 2005, 5 (04): : 276 - 276
  • [4] Cytochrome P4502D6 (CYP2D6) bioelectrode for fluoxetine
    Iwuoha, EI
    Wilson, A
    Howel, M
    Mathebe, NGR
    Montane-Jaime, K
    Narinesingh, D
    Guiseppi-Elie, A
    ANALYTICAL LETTERS, 2004, 37 (05) : 929 - 941
  • [5] Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity:: Characterization of gene duplication events
    Gaedigk, A.
    Ndjountche, L.
    Divakaran, K.
    Bradford, L. DiAnne
    Zineh, I.
    Oberlander, T. F.
    Brousseau, D. C.
    McCarver, D. G.
    Johnson, J. A.
    Alander, S. W.
    Riggs, K. Wayne
    Leeder, J. Steven
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (02) : 242 - 251
  • [6] Inhibition of cytochrome P4502D6 (CYP2D6) by terbinafine (TER) in vitro.
    Abdel-Rahman, SM
    Marcucci, K
    Boge, T
    Gotschall, RR
    Kearns, GL
    Leeder, JS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 135 - 135
  • [7] The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6)
    Rodrigues, AD
    Roberts, EM
    DRUG METABOLISM AND DISPOSITION, 1997, 25 (05) : 651 - 655
  • [8] Accuracy of cytochrome P4502D6 (CYP2D6): Phenotype assignment from genotyping data.
    Gaedigk, A
    Gotschall, RR
    Forbes, NS
    Simon, SD
    Leeder, JS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 139 - 139
  • [9] Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: Structural studies on specific CYP2D6 substrate metabolism
    Lewis, DFV
    Eddershaw, PJ
    Goldfarb, PS
    Tarbit, MH
    XENOBIOTICA, 1997, 27 (04) : 319 - 339
  • [10] Identification and characterization of cytochrome P4502D6*56B (CYP2D6*56B), a novel allele associated with the poor metabolizer phenotype.
    Gaedigk, A.
    Eklund, J. D.
    Pearce, R. E.
    Leeder, J. S.
    Alander, S. W.
    Bradford, L. D.
    Kennedy, M. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S85 - S85